Guinea

EDITORIAL: NEW YORK TIMES                                       Feb. 17, 2015
President Obama has announced that almost all of the American troops sent to West Africa to help contain the Ebola epidemic will be withdrawn soon. That makes sense because they have largely completed the work they were sent to do. The next phase of the battle will rely on public health measures carried out by local and international health workers and experts.

Despite major gains, about 100 new cases are detected each week. It will take a concerted effort, backed financially by the United States and others, to drive that number down to zero....

The main task now facing public health workers is to find all people infected with Ebola and trace and isolate all their contacts to prevent passing the virus to others. The goal is to eradicate all traces of the virus from the afflicted countries. A well-trained work force will be essential to this task. As Mr. Obama warned last week, “Every case is an ember that if not contained can light a new fire.”

Read complete editorial.

http://www.nytimes.com/2015/02/16/opinion/mission-not-yet-accomplished.html

AFP                                                                                                                    Feb. 17, 2015

London--  A team of leading international scientists on Tuesday called for new Ebola vaccines to be made available in months rather than years and warned against complacency after a reduction in infection rates.

(Scroll down for link to complete report.)

"Despite falling infection rates in west Africa, the risk that the current Ebola outbreak may not be brought completely under control remains," said Jeremy Farrar, director of the Wellcome Trust, Britain's biggest medical charity.

"The accelerated development of candidate vaccines... is essential," said Farrar, who co-chairs a group of 26 international experts on vaccine development.

Read complete story.

http://news.yahoo.com/scientists-warn-against-complacency-ebola-vaccines-004937305.html;_ylt=AwrBEiHDVuNUhDcAfsPQtDMD

Recommendations for Accelerating the Development of Ebola Vaccines: Report & Analysis

AGENCE FRANCE-PRESSE-- by Mouctar Bah                                   Feb. 15, 2015                    

Conakry  - The leaders of the countries devastated by the west African Ebola outbreak vowed at a summit in Guinea on Sunday to eradicate the virus by mid-April.

A Guinea's health worker wearing protective suit holds masks at an Ebola Donka treatment centre in Conakry on December 8, 2014 (AFP Photo/Cellou Binani)

Guinea's President Alpha Conde and his Liberian and Sierra Leone counterparts Ellen Johnson Sirleaf and Ernest Bai Koroma made the pledge after day-long closed talks in the Guinean capital Conakry.

Hadja Saran Daraba Kaba, the secretary-general of the Mano River Union bloc grouping the countries, said their presidents "commit to achieving zero Ebola infections within 60 days, effective today".

The summit came with infections having dropped rapidly across the countries, although the World Health Organization says Guinea and Sierra Leone remain a huge concern as both have seen a recent spike in new confirmed cases.

Read complete story.

CENTER FOR INFECTIOUS DISEASE AND POLICY by  Lisa Schnirring                                                      Feb. 13, 2015

Novavax yesterday announced the launch of the first human trial of its recombinant Ebola vaccine, which will make it the fourth candidate vaccine to be tested in phase 1 trials.

Novavax's product is a glycoprotein recombinant nanoparticle vaccine adjuvanted with Matrix M (Ebola GP) to boost immune response. Conducted in Australia, the study will test the safety and immunogenicity of the vaccine, with and without the adjuvant, in 230 healthy adults ages 18 to 50. Subjects will be given two intramuscular injections 3 weeks apart....

Three other Ebola vaccines are in clinical trials. Phase 2 and 3 studies of the two vaccines that are furthest along in trials got under way in Liberia at the end of January. They include two vector virus vaccines, ChAd3, developed by the National Institutes of Health (NIH) and GlaxoSmithKline (GSK), and VSV-EBOV, developed by the Canadian government and licensed by NewLink Genetics and Merck.

A phase 1 trial of a prime-boost Ebola vaccine regimen from Johnson & Johnson launched in early January in the United Kingdom.